Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
暂无分享,去创建一个
A. Evans | M. Filippi | C. Pozzilli | A. Zijdenbos | L. Kappos | P. Calabresi | C. Bever | J. Oger | M. Clanet | E. Radue | H. Przuntek | G. Comi | L. Steinman | I. Berry | H. Panitch | G. Edan | J. Antel | T. Witjas | M. Rodegher | Xin-jun Liu | E. Giugni | D. Brassat | S. Bastianello | P. Duquette | J. Pelletier | J. Castaldo | P. Crowe | Eric B. Johnson | C. Lienert | P. Conlon | A. Rae-Grant | J. Guarnaccia | A. Gaur | N. Ling | E. Katz | Volker Hoffmann | D. Alleva | D. Pöhlau | P. Bourgouin | D. Schött | P. Cozzone | I. Brunet | S. Salem | G. Johnson | P. Mills | Nancy Eckert | Alice Taksaoui | Shawki Salem